Regulus Therapeutics (RGLS) Misses Q2 EPS by 5c

Regulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.17), $0.05 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
• Capital Southwest Corporation (CSWC) Tops Q2 EPS by 2c
• Bit Origin plans 16-server Nvidia Blackwell B300 deployment in Malaysia